TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of NMS-1116354 in Advanced/Metastatic Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Advanced/metastatic solid tumors, for which no alternative effective standard therapy is available~2. Maximum of 4 regimens of prior cancer therapy allowed~3. Prior radiotherapy allowed if no more than 25% of BM reserve irradiated~4. Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer therapy~5. ECOG performance status (PS) 0 or 1~6. Adult (age \>/= 18 and \</= 80 years) patients~7. Adequate renal, liver and BM reserve~8. Capability to swallow capsules intact~Exclusion Criteria:~1. Current enrollment in another therapeutic clinical trial~2. Known brain metastases~3. Currently active second malignancy~4. Major surgery within 4 weeks prior to treatment~5. Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis~6. Pregnancy or breast-feeding women~7. Known active infections~8. Gastrointestinal disease or other malabsorption syndromes that would impact on drug absorption~9. Adrenal insufficiency~10. Other severe acute or chronic medical or psychiatric condition that could compromise protocol objectives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cardiopulmonary Effects of Bronchoalveolar Wash on Patients With Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years~* Patients intubated mechanically ventilated~* Patients with ARDS according to the new definition of Berlin~* Patients under sedation / analgesia~* Patients for whom BAL is programmed~* Collection of non-family opposition~Exclusion Criteria:~* PaO2 / FiO2 \<50 or any situation which according to investigator would create a risk to the patient during the procedure~* Persistent hypotension despite the administered therapeutic~* Patients tracheotomy~* Patients dying~* Care limitations Patients~* Known allergy to muscle relaxants~* Pregnant woman~* Patients under guardianship or under judicial protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bronchoalveolar Lavage (Type: EXPERIMENTAL): BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Fluent in English~* Right handed~* 13-17 years old~Exclusion Criteria:~* History of oral nerve damage, presence of known taste or smell disorder, food allergies or sensitivities (for example nuts, lactose, artificial sweeteners), history of CNS disease, diabetes, history of DSM-IV major psychiatric disorder, including alcohol and substance abuse, chronic use of medication that may affect taste, conditions that may interefere with gustatory or olfactory perception (colds, seasonal allergies, recent smoking history), aberrant stimulus ratings, contra-indication for fMRI, uncomfortable swallowing in supine position, discomfort or anxiety associated with insertion an intravenous catheter, regular artificial sweetener use.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Sucralose (Type: EXPERIMENTAL): Flavored beverage with sucralose.
- Sucrose (Type: EXPERIMENTAL): Flavored beverage with sucrose.
- Sucralose + maltodextrin (Type: EXPERIMENTAL): Flavored beverage with Splenda + maltodextrin .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Activity and Life-role Targeted Pain Rehabilitation in Primary Health Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persons seeking primary health care due to back, neck or shoulder pain~* Aged 18 to 60 years~* Being on sick leave or disability compensation~* Able to understand, read and write Swedish

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Activity targeted pain rehabilitation (Type: EXPERIMENTAL): A new activity and life-role targeting pain rehabilitation program (ALAR) has been developed to reduce psychosocial barriers to rehabilitation progress, promote re-integration into life-role activities and facilitate return-to-work.
- Treatment as usual (Type: ACTIVE_COMPARATOR): Usual treatment consisting of multimodal rehabilitation provided by multi-professional teams in primary health care in the County of Dalarna, Sweden.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of primary immunodeficiency (acc. WHO)~* Previous treatment with commercial Octagam 5% every 3-4 weeks for at least 6 infusions intervals~* Documented IgG trough levels of the two previous infusions before enrollment with a value of at least 5.5 g/L for both~Exclusion Criteria:~* Acute infection requiring intravenous antibiotic treatment within two weeks before screening~* Exposure to blood or any blood product or derivative other than commercially available Octagam 5%, within the past 3 months~* History of hypersensitivity to blood or plasma derived products~* Requirement of any routine premedication for IGIV treatment~* History of congenital impairment of pulmonary function~* Severe liver function impairment~* Severe renal function impairment or predisposition for acute renal failure~* History of autoimmune haemolytic anaemia~* History of diabetes mellitus~* Congestive heart failure NYHA III or IV~* Non-controlled arterial hypertension~* History of DVT or thrombotic complications with IGIV treatment~* Known infection with HIV, HCV or HBV~* Treatment with steroids, immunosuppressive or immunomodulatory drugs~* Planned vaccination during study period~* Pregnant or nursing woman

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Octagam 10% (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chronic Frontal Sinusitis by a Simple Technique Using Dilation Balloons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman of age ≥ to 18 years.~* Patient for which a frontal sinus surgery (Draf 1 type) is programmed for any type of frontal sinusitis unresponsive to drug treatment properly leads.~* Patient affiliated to a social protection scheme Written informed consent of the patient~* Signed informed consent~Exclusion Criteria:~* Polyposis sinonasal or other sinus to be the subject of a simultaneous complementary intervention~* Sinuso-nasal tumors~* Osteogenesis~* Fragile patients or patient needing gesture contraindicating surgery by rigid instrumentation~* Contraindication with balloon using~* Contraindication to general anesthesia~* Immunosuppressive therapy~* Patient under judicial protection~* Pregnancy or Breastfeeding~* Exclusion period determinated with concurrent participation in other experimental studies~* Contrast medium allergy background~* Impossibility to give the informed study documentation to the subject (emergency situation, lack of understanding, etc...)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sinuplasty balloon (Type: ACTIVE_COMPARATOR): Patients will receive the innovative health technology to treat frontal sinusitis : a balloon sinuplasty
- Conventional surgical procedure (Type: ACTIVE_COMPARATOR): Patients will be treated with the conventional procedure : a sinus surgery with rigide instrumentation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed SARS-CoV-2 infection 5 days prior to randomization~* Initial onset of COVID-19 signs/symptoms within 5 days of randomization~* Fertile participants must agree to use a highly effective method of contraception~Exclusion Criteria:~* Has at least one underlying medical condition associated with an increased risk of developing severe illness from COVID-19~* History of or need for hospitalization for the medical treatment of COVID-19~* Prior diagnosis of SARS-CoV-2 infection (reinfection)~* Known medical history of liver disease~* Receiving dialysis or have known renal impairment~* Known Human Immunodeficiency Virus (HIV) infection with viral load \> 400 copies/ml or taking prohibited medications for HIV treatment~* Suspected or confirmed concurrent active systemic infection other than COVID-19~* Current or expected use of any medications or substances that are highly dependent on Cytochrome P450 3A4 (CYP3A4) for clearance or are strong inducers of CYP3A4~* Has received or is expected to receive monoclonal antibody treatment or convalescent COVID-19 plasma~* Has received any SARS-CoV-2 vaccine within 12 months of screening~* Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19~* Known prior participation in this trial or other trial involving PF-07321332~* Oxygen saturation of \< 92% on room air~* Females who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-07321332/ritonavir (Type: EXPERIMENTAL): Orally administered PF-07321332+ritonavir
- Placebo (Type: PLACEBO_COMPARATOR): Orally administered Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Organ Donation Interventions Among High Students

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Not previously consented to organ donation~* Attending high school or GED-granting school~Exclusion Criteria:~* Non-English speaking~* Visually impaired~* Cognitively impaired

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- Health & Wellness (Type: NO_INTERVENTION): Following enrollment, participants will learn about health and wellness.
- Organ Donation Video Education (Type: EXPERIMENTAL): Following recruitment, participants will watch and discuss videos about organ donation.
- Organ Donation Discussion Education (Type: EXPERIMENTAL): Following recruitment, participants will learn techniques to introduce and discuss the topic of organ donation with parents or guardians.
- Both Video and Discussion Education (Type: EXPERIMENTAL): Following recruitment, participants will watch and discuss videos about organ donation and then learn techniques to introduce and discuss the topic of organ donation with parents and guardians.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) diagnostic criteria for schizophrenia confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) Version 7.0.2~* Participants must have well-controlled positive symptoms and prominent negative symptoms as defined by Positive and Negative Syndrome Scale (PANSS) criteria.~* Participants currently receiving a second-generation atypical antipsychotic drug (SGA) are eligible if they are stable and adherent to their dosing schedule.~* Participants must have a reliable informant (e.g., case manager, social worker, family member). The informant should be able to spend an adequate amount of time with the participant to be able to address behaviors, activities, and symptoms.~Exclusion Criteria:~* Participants with current major depressive disorder (MDD)~* Participants with pseudo-parkinsonism secondary to their ongoing antipsychotic medication~* Participants currently using anticholinergic medications~* Participants recently hospitalized as in-patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules will be administered orally twice a day over a 15-week period.
- AVP-786 (Type: EXPERIMENTAL): AVP-786 capsules will be administered orally twice a day over a 15-week period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged 18 years and above, both genders.~2. Histologically or cytologically confirmed Primary Hepatocellular Carcinoma (HCC)~3. No fibrolamellar subtype HCC~4. Not eligible for any other systemic anti-neoplastic treatment approved for HCC~5. Not eligible for Transarterial chemoembolization (TACE ).~6. No more than 1 prior systemic therapy. Previous TACE or Radiofrequency ablation (RFA) that were used for HCC, are permitted.~7. Not a candidate for curative surgical resection or liver transplantation~8. Measurable disease defined by the identification at least 1 measurable lesion by MRI using RECIST criteria. Tumor in area of TACE or RFA must be enlarging post-procedure to be considered measurable disease.~9. Alpha-fetoprotein (AFP) greater than the upper limit of normal (ULN)~10. Child's Pugh classification A~11. ECOG performance status 0-1~Exclusion Criteria:~1. Patients progressing to liver failure.~2. No core biopsy within the past 7 days~3. Patients who are eligible for Transarterial Chemoembolization (TACE)~4. Patients on concurrent anti-neoplastic therapy (including interferon)~5. Patients who have received any systemic anti-neoplastic therapy not approved for the treatment of HCC.~6. Patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids~7. Presence of metastasis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-011 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed renal cell carcinoma with metastasis.~* Must have measurable disease.~* No prior cytokine, chemotherapy, hormonal, or other immuno-based therapies (including vaccine or cellular based) for their renal cancer is allowed. No prior use of bisphosphonates will be allowed. One prior experimental therapy will be permitted as long as \> 4 weeks have passed since last drug administration.~* ECOG performance status 0 or 1~* Adequate cardiac function by history.~* Pulse-oximetry \> 92% on room air.~Exclusion Criteria:~* Radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.~* Known brain metastases~* Any history of an autoimmune disease (ie. psoriasis, inflammatory bowel disease, etc) must receive clearance by the investigator before being permitted on study due to the potential worsening of those disorders from IL-~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.~* History of myocardial infarction or hospitalization for congestive heart failure within 12 months of enrollment.~* History of prior malignancy (except basal cell carcinoma resected with curative intent) unless resected or treated with curative intent and disease free for \> 5 years.~* Any history of seizures given increased seizure risk with IL-2.~* Organ allograft (transplant) recipients will be excluded given absolute contraindication with IL-2 therapy.~* Pregnant women are excluded~* Patients on systemic steroids (oral or IV) will not be eligible for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Interleukin-2 subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles in combination with Zoledronic acid IV on day 1 of every 4 week (28 days) cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed incurable primitive neuroectodermal tumors outside the central nervous system that are unlikely to respond to existing therapy, meeting 1 of the following criteria:~  * Metastatic disease~ * Progressive, recurrent, or refractory disease after initial therapy, including surgery, chemotherapy, and/or radiotherapy~* Measurable disease by MRI or CT scan~* Tumor must be at least 2 cm~PATIENT CHARACTERISTICS:~Age:~* 6 months and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* No renal insufficiency~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No active infection~* No nonmalignant systemic disease~* Not a high medical or psychiatric risk~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy~* No concurrent immunomodulating agents~Chemotherapy:~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* See Disease Characteristics~* At least 8 weeks since prior radiotherapy~Surgery:~* See Disease Characteristics~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplastons~* No other concurrent antineoplastic agents

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues